<?xml version="1.0" encoding="UTF-8"?>
<ref id="cit0048">
 <label>48.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Koch</surname>
    <given-names>T</given-names>
   </name>, 
   <name name-style="western">
    <surname>Dahlke</surname>
    <given-names>C</given-names>
   </name>, 
   <name name-style="western">
    <surname>Fathi</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kupke</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Krähling</surname>
    <given-names>V</given-names>
   </name>, 
   <name name-style="western">
    <surname>Okba</surname>
    <given-names>NM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hesterkamp</surname>
    <given-names>T</given-names>
   </name>
  </person-group>
  <article-title>Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial</article-title>. 
  <source>The Lancet Infect Dis</source>. 
  <year>2020</year>;
  <volume>20</volume>:
  <fpage>827</fpage>–
  <lpage>38</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30248-6</pub-id>.
  <pub-id pub-id-type="pmid">32325037</pub-id>
 </mixed-citation>
</ref>
